4 years ago

Sense Biodetection Secures $15 Million to Expand COVID-19 Testing

  • Sense Biodetection, a UK-based diagnostics company, secured an additional $15 million in its Series B funding round, bringing the total raised to $65 million

  • The round was led by existing investor Koch Disruptive Technologies (KDT)

  • The funding will be used to support the commercial launch of the company's COVID-19 Test in the US and Europe.

      • ProblemHealthcare

      "Sense Biodetection aims to address the need for accurate, rapid, and accessible COVID-19 testing by developing a molecular diagnostics platform that delivers lab-quality results without the need for instruments."

      Solution

      "The Veros™ platform is designed to provide rapid, disposable molecular tests for COVID-19, enhancing patient access to testing and improving patient health outcomes while reducing overall healthcare costs."

      Covered on